Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2.

@article{Wang2014BortezomibPO,
  title={Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2.},
  author={Zhiyu Wang and Juan Wang and Xing Li and Ligang Xing and Yan Ding and Penghui Shi and Yuehua Zhang and Shenghu Guo and Xin Shu and Bao-qing Shan},
  journal={International journal of oncology},
  year={2014},
  volume={45 4},
  pages={
          1469-78
        }
}
Prostate cancer is the most common malignancy diagnosed in males, and bone metastases remain a significant source of morbidity and mortality in this population. Ubiquitin ligase E3s and proteasomes were thought to play essential roles in the development of cancers, therefore, they were proposed as therapy targets for the treatment of solid and hematological malignancies. Bortezomib, well-known as a proteasome inhibitor, has been observed with exact anticancer effect both in cell and animal… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases

P G Whang, S C Gamradt, J J Gates, J R Lieberman
  • Prostate Cancer and Prostatic Diseases
  • 2005
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
VIEW 1 EXCERPT